HeartSciences Statistics
Total Valuation
HeartSciences has a market cap or net worth of $2.44 million. The enterprise value is -$916,083.
Important Dates
The next estimated earnings date is Thursday, December 12, 2024, after market close.
| Earnings Date | Dec 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HeartSciences has 913,321 shares outstanding. The number of shares has increased by 471.27% in one year.
| Current Share Class | 913,321 |
| Shares Outstanding | 913,321 |
| Shares Change (YoY) | +471.27% |
| Shares Change (QoQ) | +18.91% |
| Owned by Insiders (%) | 9.33% |
| Owned by Institutions (%) | 7.00% |
| Float | 828,115 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 73.97 |
| Forward PS | 0.74 |
| PB Ratio | 0.40 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.49, with a Debt / Equity ratio of 0.17.
| Current Ratio | 4.49 |
| Quick Ratio | 3.21 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.72 |
Financial Efficiency
Return on equity (ROE) is -269.29% and return on invested capital (ROIC) is -110.04%.
| Return on Equity (ROE) | -269.29% |
| Return on Assets (ROA) | -81.69% |
| Return on Capital (ROIC) | -110.04% |
| Revenue Per Employee | $1,240 |
| Profits Per Employee | -$486,003 |
| Employee Count | 15 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.01 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.27% in the last 52 weeks. The beta is 3.29, so HeartSciences's price volatility has been higher than the market average.
| Beta (5Y) | 3.29 |
| 52-Week Price Change | -86.27% |
| 50-Day Moving Average | 3.39 |
| 200-Day Moving Average | 6.46 |
| Relative Strength Index (RSI) | 36.13 |
| Average Volume (20 Days) | 27,652 |
Short Selling Information
The latest short interest is 23,081, so 2.53% of the outstanding shares have been sold short.
| Short Interest | 23,081 |
| Short Previous Month | 20,574 |
| Short % of Shares Out | 2.53% |
| Short % of Float | 2.79% |
| Short Ratio (days to cover) | 0.49 |
Income Statement
In the last 12 months, HeartSciences had revenue of $18,600 and -$7.29 million in losses. Loss per share was -$13.99.
| Revenue | 18,600 |
| Gross Profit | 12,519 |
| Operating Income | -7.05M |
| Pretax Income | -6.61M |
| Net Income | -7.29M |
| EBITDA | -7.02M |
| EBIT | -7.05M |
| Loss Per Share | -$13.99 |
Full Income StatementBalance Sheet
The company has $4.34 million in cash and $1.01 million in debt, giving a net cash position of $3.33 million or $3.64 per share.
| Cash & Cash Equivalents | 4.34M |
| Total Debt | 1.01M |
| Net Cash | 3.33M |
| Net Cash Per Share | $3.64 |
| Equity (Book Value) | 5.93M |
| Book Value Per Share | 6.55 |
| Working Capital | 4.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.68 million and capital expenditures -$64,455, giving a free cash flow of -$6.75 million.
| Operating Cash Flow | -6.68M |
| Capital Expenditures | -64,455 |
| Free Cash Flow | -6.75M |
| FCF Per Share | -$7.39 |
Full Cash Flow StatementMargins
| Gross Margin | 67.31% |
| Operating Margin | -37,907.43% |
| Pretax Margin | -39,193.77% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -32,981.94% |
Dividends & Yields
HeartSciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -471.27% |
| Shareholder Yield | -471.27% |
| Earnings Yield | -302.34% |
| FCF Yield | -279.91% |
Analyst Forecast
The average price target for HeartSciences is $15.00, which is 461.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.00 |
| Price Target Difference | 461.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 17, 2024. It was a reverse split with a ratio of 0.01:1.
| Last Split Date | May 17, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.01:1 |
Scores
HeartSciences has an Altman Z-Score of -12.29 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.29 |
| Piotroski F-Score | 4 |